This study is completed in the United States. It is testing TNX-102 SL 5.6 mg Taken Daily at Bedtime for PTSD.
PTSDDrugFrom 18 Years to 75 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether TNX-102 SL 5.6 mg may be useful for adults experiencing ptsd.
What would participation involve?
Participants may receive TNX-102 SL 5.6 mg, attend study visits with the research team. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for adults with ptsd.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
United States · 16 sites
Little Rock
Little Rock, Arkansas
Site status: Not listed — confirm with the team
Beverly Hills
Beverly Hills, California
Site status: Not listed — confirm with the team
Oceanside
Oceanside, California
Site status: Not listed — confirm with the team
Orange
Orange, California
Site status: Not listed — confirm with the team
Temecula
Temecula, California
Site status: Not listed — confirm with the team
Colorado Springs
Colorado Springs, Colorado
Site status: Not listed — confirm with the team
Norwich
Norwich, Connecticut
Site status: Not listed — confirm with the team
Tampa
Tampa, Florida
Site status: Not listed — confirm with the team
Atlanta
Atlanta, Georgia
Site status: Not listed — confirm with the team
New Bedford
New Bedford, Massachusetts
Site status: Not listed — confirm with the team
Las Vegas
Las Vegas, Nevada
Site status: Not listed — confirm with the team
Cedarhurst
Cedarhurst, New York
Site status: Not listed — confirm with the team
New York
New York, New York
Site status: Not listed — confirm with the team
Canton
Canton, Ohio
Site status: Not listed — confirm with the team
Cincinnati
Cincinnati, Ohio
Site status: Not listed — confirm with the team
Oklahoma City
Oklahoma City, Oklahoma
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
Based on the public registry summary, this study is trying to understand: Evaluate the long-term safety of TNX-102 SL 5.6 mg taken daily at bedtime over an additional 40 weeks in patients with PTSD who have participated in a double-blind lead-in study and completed an initial 12-week open-label extension study (TNX-CY-P303). The study team can confirm the exact objective and what it means for you.
Does this study involve a medication?
This appears to be a medication / drug study involving TNX-102 SL 5.6 mg. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with ptsd; age range: From 18 Years to 75 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Tonix Pharmaceuticals, Inc., which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
